REGLAN (metoclopramide hydrochloride) by Pfizer is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 1983.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
REGLAN (metoclopramide HCl) is a small-molecule dopamine antagonist that enhances upper GI motility and prevents nausea/vomiting by blocking central and peripheral dopamine receptors. It accelerates gastric emptying, increases lower esophageal sphincter pressure, and is used for gastroesophageal reflux, diabetic gastroparesis, and chemotherapy-induced nausea. The drug works by sensitizing GI tissues to acetylcholine and blocking dopamine-mediated stimulation of the chemoreceptor trigger zone.
Product is in late-stage decline with limited Medicare claims, indicating reduced market opportunity and likely smaller team size focused on cost management and generic transition strategy.
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on REGLAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moREGLAN offers limited career growth opportunities as a legacy product in steep decline with minimal linked job openings and low commercial activity. Roles available are primarily defensive (cost management, generic transition, compliance) rather than growth-oriented, making this product less attractive for ambitious early-career professionals seeking high-impact assignments.